SynthesisNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2026
Elevated neurofilament light chain (NfL) in blood and CSF as a biomarker for Parkinson's disease cognitive impairment: A meta-analysis.
Synthesis in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundParkinson’s disease (PD), a progressive neurodegenerative disorder, is linked to cognitive impairment. Neurofilament light chain (NfL) may serve as a biomarker, but its association with cognitive decline in PD remains inconsistent.
methodsWe searched PubMed, Embase, Scopus and Web of Science, identifying 19 eligible studies based on predefined criteria. Methodological quality was assessed using Newcastle–Ottawa Scale (NOS). Diagnostic discriminative performance of NfL was quantified through area under the curve (AUC) with 95% confidence intervals (CI) as effect measure. Meta-analysis employed random-effects models, followed by subgroup analysis, meta-regression, bias risk assessment, and sensitivity analysis.
resultsNfL demonstrated moderate-to-high diagnostic accuracy across three PD cognitive states (pooled AUC = 0.74, 95% CI: 0.70–0.79, P < 0.001), with NfL levels progressively increasing alongside worsening cognitive impairment—from PD with no cognitive impairment (PD-NC) to PD with mild cognitive impairment (PD-MCI) and PD dementia (PDD). Pairwise comparisons revealed AUC values of 0.70 (95% CI: 0.64–0.76) for PD-NC vs. PD-MCI, 0.75 (95% CI: 0.65–0.85) for PD-MCI vs. PDD, and 0.79 (95% CI: 0.73–0.86) for PD-NC vs. PDD. Plasma NfL (AUC = 0.75, 95% CI: 0.70–0.81, P < 0.001) slightly outperformed cerebrospinal fluid NfL (AUC = 0.72, 95% CI: 0.69–0.75, P < 0.001) in reflecting cognitive status and Mini-Mental State Examination (MMSE) scale showed superior utility over Montreal Cognitive Assessment (MoCA) evaluating NfL-cognitive impairment relationship.
conclusionNfL levels are closely associated with severity of cognitive impairment in PD patients and may be a potential biomarker for evaluating cognitive decline.
Indexed as
Identifiers
41507682What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.